Innate Pharma S.A. Sponsored ADR (NASDAQ:IPHA) Short Interest Update

Innate Pharma S.A. Sponsored ADR (NASDAQ:IPHA) was the target of a large decline in short interest in February. As of February 13th, there was short interest totaling 125,617 shares, a decline of 40.3% from the January 29th total of 210,405 shares. Approximately 0.2% of the company’s stock are short sold. Based on an average trading volume of 20,805 shares, the days-to-cover ratio is presently 6.0 days. Based on an average trading volume of 20,805 shares, the days-to-cover ratio is presently 6.0 days. Approximately 0.2% of the company’s stock are short sold.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently modified their holdings of the company. Millennium Management LLC acquired a new position in shares of Innate Pharma in the fourth quarter valued at approximately $36,000. OLD Mission Capital LLC bought a new position in Innate Pharma during the 4th quarter worth $50,000. Finally, Jane Street Group LLC bought a new position in Innate Pharma during the 4th quarter worth $162,000. Institutional investors own 0.16% of the company’s stock.

Wall Street Analyst Weigh In

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of Innate Pharma in a report on Thursday, January 22nd. One analyst has rated the stock with a Strong Buy rating, one has issued a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $5.00.

Innate Pharma Trading Down 1.4%

IPHA opened at $1.72 on Friday. The business’s 50-day simple moving average is $1.75 and its 200 day simple moving average is $1.90. Innate Pharma has a 52-week low of $1.57 and a 52-week high of $2.63.

About Innate Pharma

Innate Pharma SA is a clinical-stage biotechnology company specializing in the discovery and development of antibody-based therapies that harness the body’s innate immune system to combat cancer. Founded in 1999 and headquartered in Marseille, France, the company pioneers novel monoclonal antibodies designed to activate natural killer cells and macrophages, offering a complementary approach to existing immuno-oncology treatments.

The company’s lead program, monalizumab, targets the NKG2A immune checkpoint receptor and is being developed in collaboration with AstraZeneca.